Literature DB >> 1875692

Recent progress in bone induction by osteogenin and bone morphogenetic proteins: challenges for biomechanical and tissue engineering.

A H Reddi1, N S Cunningham.   

Abstract

Implantation of demineralized bone matrix results in local bone induction. Bone induction is a sequential biological chain reaction that consists of chemotaxis and proliferation of mesenchymal cells and differentiation of bone. Osteogenin, a bone morphogenetic protein has been purified and the amino acid sequence determined. Recently a family of bone morphogenetic proteins have been cloned and expressed by recombinant DNA technology. The availability of growth and morphogenetic factors will permit the rational design of new bone. The challenge for the biomechanical engineer is to attain mechanically optimal and functionally adaptive new bone for various skeletal prostheses. We are on the threshold for fabrication of new bone based on sound architectural design principles of tissue engineering based on cellular and molecular biology of growth and differentiation factors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1875692     DOI: 10.1115/1.2891233

Source DB:  PubMed          Journal:  J Biomech Eng        ISSN: 0148-0731            Impact factor:   2.097


  3 in total

1.  Evaluation of bone matrix and demineralized bone matrix incorporated PLGA matrices for bone repair.

Authors:  A Champa Jayasuriya; Nabil A Ebraheim
Journal:  J Mater Sci Mater Med       Date:  2009-03-29       Impact factor: 3.896

2.  TNF-alpha upregulates expression of BMP-2 and BMP-3 genes in the rat dental follicle--implications for tooth eruption.

Authors:  Shaomian Yao; Veronica Prpic; Fenghui Pan; Gary E Wise
Journal:  Connect Tissue Res       Date:  2010       Impact factor: 3.417

3.  Cell spheroids are as effective as single cells suspensions in the treatment of critical-sized bone defects.

Authors:  Lisa Findeisen; Julia Bolte; Corina Vater; Cathleen Petzold; Mandy Quade; Lars Müller; Stuart B Goodman; Stefan Zwingenberger
Journal:  BMC Musculoskelet Disord       Date:  2021-04-30       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.